Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

YEE HOP

Yee Hop Holdings Limited 義合控股有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 1662)

VOLUNTARY ANNOUNCEMENT ENTERING INTO THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT

This is a voluntary announcement made by Yee Hop Holdings Limited (“Yee Hop Holdings” or the “Company”, together with its subsidiaries, the “Group”). The board of directors of the Company is pleased to announce that, on 7 September 2020, BGI Marine Sci & Tech Co., Ltd.* (深圳華大海洋科技有限公司) (“BGI Marine”), a non-wholly owned subsidiary of the Company entered into a non-legally binding strategic cooperation framework agreement (the “Framework Agreement”) with BGI Life Research Institution* (深 圳華大生命科學研究院) (“BGI Research”) in relation to establishing a long-term strategic partnership to foster marine technology innovation and industry development with the use of genetic technology.

Subject Matter of the Framework Agreement:

1. BGI Research and BGI Marine (the “Parties”) intend to establish a long-term cooperative partnership. During close cooperation, both Parties will further strengthen their respective advantages to achieve mutual interests and benefits.

2. By jointly establishing research and development (R&D) projects, and addressing keynote issues in the global marine organism resources and industry application areas, the Parties will efficiently explore genetic resources of marine flagship species; accelerate further cooperation in various fields, including data analysis of marine organism , construction of big database of marine organisms, marine organism molecular breeding, R&D of marine biological drugs, synthesis of marine bio-active substances, technology development of stereoscopic agriculture and processing of marine bioproducts; and foster marine technology innovation and industry development with the use of genetic technology.

– 1 – Information on BGI Research

BGI Research is an institution under BGI Shenzhen Co., Ltd.* (深圳華大基因科技有限公 司) (“BGI Group”), as well as one of the top ten basic research institutions in Shenzhen city approved by the local authority. It is a non-profit organization committed to multi- omics research and development in areas such as life sciences, and medical applications. BGI Research has been deepening its foothold in the field of genomics over the years with a view to promoting the development of biotechnology and the enhancement of public health. It is at the international forefront of research of the basics and applications of genomics and related technological development, and provides technical support for the industrialization of genomics research results. The institution integrates genomics science research with the long-term development projects of personalized medicine and engages in public welfare projects relating to low-cost healthcare for the entire population. There are five research institutions under BGI Research, namely Institute of Biochemistry, Institute of Biointelligence Technology, Institute of Precision Health, Institute of Digital Earth and Institute of Super Cell.

To the best of the knowledge, information and belief of the directors after having made all reasonable enquiries, BGI Research, BGI Group and their respective ultimate beneficial owners are all independent third parties.

Information on BGI Marine

In 2019, the Group completed the acquisition of 70% equity interests in BGI Marine originally owned by BGI Group. BGI Marine is an integrated technological-based aquaculture group adopting state-of-the-art breeding technology of aquatic products. It is principally engaged in the research, breeding, sales and trading of aquatic products.

Reasons for Entering into the Strategic Cooperation Framework Agreement

Reference is made to the annual report for 2019/20 of the Company, which discloses that, upon completing the acquisition of BGI Marine, the Group has further expanded its business into various fields, such as protection and exploitation of aquatic genetic recourses, molecular breeding of aquatic products, ecology and industrial processing of aquaculture products as well as import and export trading. Looking ahead, the Group will continue its strategy to diversify the business spectrum and to broaden the revenue base of the Group. In addition, the Group will consolidate and improve the Aquatic Giga Data of BGI Marine to develop functional food and aquatic biopharmaceuticals by further utilizing the advantages of massive research of aquatic organism omics. At the same time, by leveraging the existing advantages of aquatic biological drugs and aquatic bioengineering during its industrial expansion, the Group is looking for opportunities to conduct research and cooperation with scientists in domestic and international professional fields on the development of new industries.

– 2 – In order to enhance the production capability of BGI Marine to increase its sales revenue, the Group has actively promoted and planned to construct additional bases and centers for science research services and development by entering into letters of intent for strategic cooperation/ agreements of intent for project investment/cooperation framework agreements with relevant parties which possess abundant resources in various coastal provinces and municipalities. We aim to develop BGI Marine into a world leading organization in the marine biology industry.

As a world leading genomics research institute, BGI Research possesses extensive and advanced expertise in medical and pharmaceutical research based on a mass amount of genetic sequence tests. BGI Marine focuses on marine organism research and follows the “Ocean Power” and “One Belt, One Road” initiatives to facilitate the transformation and upgrading of marine biology economy by leveraging on the solid technology support from its genomics sequencing and analysis platform. As part of the strategy to diversify the business spectrum and to broaden the revenue base of the Group as previously disclosed in the 2019/20 annual report of the Company, this cooperation will consolidate the Parties’ strengths and expediate the production of precise biology drugs, thereby benefitting the Group’s development of marine ecology business.

Having considered the abovementioned reasons, the directors are of the view that entering into the Framework Agreement was conducted in the ordinary and usual course of business of the Group and in the interests of the Company and the shareholders as a whole.

General

The Framework Agreement only provides a framework for the cooperation between the Group and BGI Research. The terms of cooperation contemplated under the Framework Agreement are subject to the terms of any specific agreement which the Group and BGI Research may subsequently enter into from time to time. As of the date of this announcement, the Group and BGI Research have not entered into any agreement in respect of any specific cooperation project. In the event that any transaction contemplated under the Framework Agreement constitutes a disclosable transaction of the Company under the Listing Rules, the Company will make further announcements as appropriate in compliance with the Listing Rules. Shareholders and investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board Yee Hop Holdings Limited Jim Yin Kwan Jackin Chairman and Executive Director

Hong Kong, 7 September 2020

* For identification only

As at the date of this announcement, the executive Directors of the Company are Mr. Jim Yin Kwan Jackin, Mr. Chui Mo Ming, Mr. Yan Chi Tat, Mr. Leung Hung Kwong Derrick and Mr. Xu Jun Min; and the independent non-executive Directors are Mr. Lee Luk Shiu, Mr. Yu Hon Kwan and Mr. Wong Chi Keung Johnny.

– 3 –